JPC vs SLS Comparison

Nuveen Preferred & Income Opportunities Fund is a diversified closed-end management investment company. Its primary investment objective is to provide high current income, and its secondary investment objective is total return. The fund invests a majority of its assets in preferred securities and other income-producing securities, including hybrid securities such as contingent capital securities, and the rest of its investments are made in other securities, mainly income-oriented securities such as corporate and taxable municipal debt and common equity.

SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.